Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

A longitudinal study published in The Lancet Neurology using Alamar Biosciences' NULISAseq CNS 120 panel found that patients receiving lecanemab for early symptomatic Alzheimer's disease show markedly different biological responses. The research revealed that biomarkers associated with amyloid clearance differ from those associated with cognitive decline, explaining why clearing amyloid doesn't produce uniform clinical benefits across patients. The study measured 130 plasma proteins across 2,385 samples from 1,967 participants.

09/24/2026, 6:51 PM • GlobeNewswire

Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究

Alamar Biosciences announced a national-scale proteomics initiative in collaboration with Washington University, University of Wisconsin, and Indiana University to analyze approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using its NULISAseq Neuro 220 multiplex panel. The resulting open-access dataset will be linked to the National Alzheimer's Coordinating Center and will support AI-driven biomarker discovery and validation for neurodegenerative diseases.

07/13/2026, 12:51 PM • GlobeNewswire

Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划，推进神经退行性疾病血液生物标志物相关研究

Alamar Biosciences announced a national research initiative in collaboration with top universities to analyze approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using its NULISAseq™ Neuro 220 detection kit. The resulting dataset will be made publicly available through the National Alzheimer's Coordinating Center to support AI-driven research and accelerate biomarker discovery for neurodegenerative diseases.

07/13/2026, 12:51 PM • GlobeNewswire

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Alamar Biosciences announced a partnership with leading research universities to launch a national-scale proteomics initiative profiling approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias participants using its NULISAseq Neuro 220 panel. The resulting dataset will be publicly accessible and open to AI-driven discovery through a national data challenge, advancing biomarker discovery for neurodegenerative diseases.

07/13/2026, 2:30 AM • GlobeNewswire

Alamar Biosciences 的 NULISA 數據將於 AAIC 2026 上超過 140 場科學簡報會中亮相，突顯基於血液的阿茲海默症生物標記剖析之最新進展

Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) in London. The company highlighted advances in blood-based biomarker profiling, particularly the eMTBR-Tau and BD-pTau217 tests, which can be measured simultaneously with 220+ CNS-related proteins in a single workflow. This represents a four-fold increase from the previous AAIC conference, demonstrating growing adoption of the technology in Alzheimer's research.

07/10/2026, 7:24 PM • GlobeNewswire

AAIC 2026 逾 140 份学术报告均采用 Alamar Biosciences NULISA 数据，彰显阿尔茨海默病血液生物标志物分析领域的进展

Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) 2026 in London. The company introduced its first multiplex blood immunoassay for eMTBR-Tau, a key Alzheimer's biomarker, which can be detected alongside over 220 disease-related proteins in a single workflow. The data demonstrates that combined detection of BD-pTau217 and eMTBR-Tau improves disease stratification compared to single biomarker testing.

07/10/2026, 7:24 PM • GlobeNewswire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest purchased shares in SpaceX, Roblox, and Alamar Biosciences on Monday. SpaceX has stabilized after a volatile IPO week, trading just 3% above its first-day price despite peaking at much higher levels. Roblox faces headwinds with declining sequential user metrics despite year-over-year growth. Alamar Biosciences, a newly public proteomics company, is generating revenue and trading near its IPO price.

06/23/2026, 11:07 AM • The Motley Fool

Alamar Biosciences Reports First Quarter 2026 Financial Results

Alamar Biosciences reported record Q1 2026 revenue of $26.0 million, nearly doubling year-over-year, driven by strong consumables growth and increased instrument placements. The company completed its IPO in April 2026, raising $197.8 million in net proceeds. Despite revenue growth and improved gross margins, the company posted a net loss of $21.3 million, including an $8.6 million loss from convertible note remeasurement.

05/08/2026, 8:00 AM • GlobeNewswire